RegenETP Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

RegenETP şirketinin son birkaç yıldaki performansına ilişkin yeterli veri bulunmamaktadır.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	n/a
Net Marj	n/a
Son Kazanç Güncellemesi	31 Mar 2023

Yakın geçmiş performans güncellemeleri

Recent updates

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

May 10

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Feb 19

PolarityTE to raise up to $10M with at-the-market offering

Jan 12

PolarityTE under pressure on pricing $8M registered direct offering

Dec 22

PolarityTE perks up after securing first U.S. patent

Nov 30

PolarityTE EPS beats by $0.02, beats on revenue

Nov 09

Gelir ve Gider Dağılımı

RegenETP nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:RGTP.Q Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 23	0	-8	11	10
31 Dec 22	1	-8	15	11
30 Sep 22	2	-16	18	12
30 Jun 22	3	-13	19	13
31 Mar 22	5	-17	22	15
31 Dec 21	9	-30	23	14
30 Sep 21	12	-32	25	13
30 Jun 21	14	-38	29	12
31 Mar 21	14	-47	30	11
31 Dec 20	10	-43	36	12
30 Sep 20	8	-54	48	13
30 Jun 20	6	-70	62	13
31 Mar 20	5	-80	73	14
31 Dec 19	6	-92	80	16
30 Sep 19	7	-128	117	21
30 Jun 19	7	-125	113	22
31 Mar 19	6	-116	105	21
31 Dec 18	4	-111	92	21
31 Oct 18	2	-74	51	19
31 Jul 18	0	-62	39	17
30 Apr 18	0	-50	26	18
31 Jan 18	0	-141	25	118
31 Oct 17	0	-131	19	112
31 Jul 17	0	-121	13	108
30 Apr 17	-1	-118	13	105
31 Jan 17	-1	-8	8	0
31 Oct 16	0	-10	4	0
31 Jul 16	0	-10	5	0
30 Apr 16	3	-9	5	0
31 Jan 16	4	-11	5	0
31 Oct 15	7	-6	6	0
31 Jul 15	13	-11	9	0
30 Apr 15	14	-13	10	1
31 Jan 15	16	-13	12	1
31 Oct 14	34	-16	16	2
31 Jul 14	38	-15	16	3
30 Apr 14	39	-16	16	4
31 Jan 14	46	-15	17	5

Kaliteli Kazançlar: RGTP.Q yüksek düzeyde nakit dışı kazança sahiptir.

Büyüyen Kar Marjı: RGTP.Q 'nin kâr marjlarının geçen yıl boyunca iyileşip iyileşmediğini belirlemek için yeterli veri yok.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: RGTP.Q 'un son 5 yılda yıllık kazanç büyüme oranının pozitif olup olmadığını belirlemek için yeterli veri yok.

Büyüme Hızlandırma: RGTP.Q 'in geçmiş yıl kazanç büyümesinin 5 yıllık ortalamayla karşılaştırılmasına yetecek veri yok.

Kazançlar vs. Sektör: RGTP.Q şirketinin geçen yılki kazanç büyümesinin Biotechs sektör ortalamasını aşıp aşmadığını belirlemek için yeterli veri yok.

Özkaynak Getirisi

Yüksek ROE: RGTP.Q hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( 0% ) sahiptir.

RegenETP Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Recent updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index

New major risk - Share price stability

PolarityTE's Common Stock To Be Delisted From Nasdaq

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$1.25

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE).

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Consensus revenue estimates fall by 40%

Price target decreased to US$15.38

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PolarityTE down 10% on lower-than-expected Q2 revenue

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

Price target decreased to US$15.38

First quarter 2022 earnings: Revenues miss analyst expectations

PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R)

PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$1.08

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely?

PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone

PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application

Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn Situation

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc

Independent Director Minnie Baylor-Henry has left the company

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

Consensus forecasts updated

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)

PolarityTE Is Not A DeFi Coin

Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet?

Independent Chairman of the Board recently bought US$259k worth of stock

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)

PolarityTE, Inc. Updates on SkinTE Biologic License Application

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Analysts update estimates

PolarityTE, Inc. Announces Submission of an Investigational New Drug Application

New 90-day high: US$1.54

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.

PolarityTE to raise up to $10M with at-the-market offering

New 90-day high: US$1.32

PolarityTE under pressure on pricing $8M registered direct offering

New 90-day low: US$0.63

PolarityTE perks up after securing first U.S. patent

Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.18 loss per share